Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

Published:2017-05 Issue:3 Volume:18 Page:281-285
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lara Matthew S.,Holland William S.,Chinn Danielle,Burich Rebekah A.,Lara Primo N.,Gandara David R.,Kelly Karen,Mack Philip C.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans;Arteaga;Cancer Cell,2006

2. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways;Sordella;Science,2004

3. Clinicopathologic characteristics of the EGFR gene mutation in non–small cell lung cancer;Tsao;J Thorac Oncol,2006

4. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials;Bell;J Clin Oncol,2005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance of MET alterations in non-small cell lung cancer and currently available therapies;Malignant tumours;2023-11-08

2. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non‐small cell lung cancer cells;BioFactors;2023-08-09

3. Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer;Therapeutic Advances in Medical Oncology;2023-01

4. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library;European Journal of Pharmacology;2023-01

5. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation;Lung Cancer: Targets and Therapy;2022-05